TheTechno Optimist.

Olezarsen (Tryngolza)Ionis Pharmaceuticals—FDA approves Tryngolza (olezarsen) for severe hypertriglyceridemia (sHTG); first indication for acute pancreatitis reduction

Olezarsen (Tryngolza)

by Ionis PharmaceuticalsUS

ASO silencing APOC3 mRNA to block the protein that inhibits triglyceride breakdown. Approved for familial chylomicronemia and severe hypertriglyceridemia.

DeployStage 4 of 5

FDA-approved for FCS (Dec 2024) and sHTG (June 2026); first ASO to reduce pancreatitis.

Updated Jun 2026Checked 10 Oct0 updates this week

Milestones

Next · Commercial launch and patient access
  1. FDA approval for familial chylomicronemia syndrome (FCS)Dec 2024Complete.
  2. Phase 3 CORE and CORE2 show 72% TG reductionSep 2025Complete.
  3. FDA Priority Review acceptance for sHTG2025Complete.
  4. FDA approves for severe hypertriglyceridemiaJun 2026Complete.
  5. Commercial launch and patient accessTarget 2026Current milestone.

Most important updates

Upcoming

  1. 2026Commercial launch and patient access (next)
  2. 2027Long-term safety and efficacy monitoring
Primer